The Effect of Early Initiation of SGLT2 Inhibitors in Reducing Heart Failure Events After MI

Effect of pre-reperfusion SGLT2 Inhibitors in patient with acute myocardial infarction on infarct size and ventricular function

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211024002

Enrollment

Registered

2021-10-24

Start date

2021-12-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis of STEMI and able to receive primary PCI within 12 hours after the onset of symptoms. STEMI repercussion injury CMR troponin mitochondria function

Interventions

All the patients who provide written informed consent will be randomly assigned to receive either dapaglifozin 20 mg loading dose and follow by dapaglifozin 10 mg once daily or placebo with 1:1 ratio.

Experimental Drug,Placebo Comparator Drug

SGLT2i,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Male or female patients older than 18 years of age 2.Diagnosis of STEMI and able to receive primary PCI within 12 hours after the onset of symptoms. 3.Coronary angiography shows occluded or reduced flow or evidence of thrombus at culprit artery 4.Occlusion site in proximal or mid segment of major epicardial artery

Exclusion criteria

Exclusion criteria: 1.Cardiogenic shock or cardiac arrest before randomization 2.Planned CABG or cardiac surgery within next 6 months 3.Stroke or TIA 1 month prior to the screening 4.History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time 5.Impaired renal function, defined as eGFR < 30 ml/min (MDRD formula) at screening 6.Diagnosis of Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA) 7.Life expectancy < 1 year 8.Prior used of SGLT2i before enrollment 9.Unable to receive SGLT2i per oral 10.Prior history of myocardial infarction 11.Any contraindication for MRI 12.Bypass graft or stent thrombosis lesion 13.Coronary collateral supply (Rentrop grade more than 2) to the culprit artery 14.Planned stage PCI after day 4 of index procedure 15.Pregnancy 16.Contraindications to heparin or antiplatelet therapy

Design outcomes

Primary

Measure	Time frame
myocardial size 3 to 5 days post MI area under the curve of cardiac troponin	—

Secondary

Measure	Time frame
myocardial infarct size acute phase and 3 months myocardial salvage index,microvascular obstruction acute phase percent MVO,myocardial infarct size acute phase and 3 months LVEF, LVEDV, LVESV	—

Countries

Thailand

Contacts

Public ContactPannipa Suwannasom

Faculty of Medicine, Chiang Mai University

pannipa_100@hotmail.com0899167893

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026